share_log

Endexx Significantly Expands Distribution Network and Revenue Through Acquisition of Controlling Interest in Non-Nicotine Vape Producer, Hyla

Endexx Significantly Expands Distribution Network and Revenue Through Acquisition of Controlling Interest in Non-Nicotine Vape Producer, Hyla

Endexx通过收购非尼古丁Vape生产商Hyla的控股权大幅扩大分销网络和收入
GlobeNewswire ·  2022/09/08 05:36

Endexx Corporation

Endexx公司

Endexx Acquires Hyla
Endexx收购Hyla

Hyla Maintains International Distribution in 10 Countries, Including at Internationally Renowned UK Department Store, Harrods

Hyla在10个国家保持国际分销,其中包括国际知名的英国百货公司Harrods

CAVE CREEK, Ariz., Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Endexx Corporation (OTC:EDXC), a provider of innovative, plant-based, and sustainable health and skincare products, today announces the acquisition of a controlling interest in Hyla US Holdco Limited, a producer and distributor of organic, plant-based, all-natural, zero-nicotine vape products.

亚利桑那州洞穴克里克,9月2022年8月8日(Global Newswire)--Via NewMediaWire-Endexx Corporation(场外交易市场代码:EDXC)今天宣布收购Hyla US Holdco Limited的控股权,Hyla US Holdco Limited是有机、植物、全天然、零尼古丁电子烟产品的生产商和分销商。

The acquisition provides two key benefits to Endexx in the near term:

此次收购在短期内为Endexx带来了两个关键好处:

  • an expanded international distribution network in 10 countries - Dubai, Saudi Arabia, the United Kingdom, the Czech Republic, Slovakia, Germany, France, the Kingdom of Bahrain, Egypt, and Switzerland, which Endexx expects will provide further leverage for sales of its men's skin care line, Blesswell, as well as its CBD products designed for pain under its CBD Unlimited brand; and
  • a significant increase in Endexx's consolidated revenues, based on Hyla's distribution and sales to date of its non-nicotine, vegan vape products.
  • 在迪拜、沙特阿拉伯、英国、捷克共和国、斯洛伐克、德国、法国、巴林王国、埃及和瑞士等10个国家扩大国际分销网络,Endexx预计这将为其男士护肤品系列Bless well以及其CBD无限品牌下专为疼痛设计的CBD产品的销售提供进一步的杠杆作用;以及
  • 基于Hyla迄今对其非尼古丁、素食Vape产品的分销和销售,Endexx的综合收入大幅增长。

"This acquisition is an important opportunity for Endexx, as the ability to expand the distribution for our CBD and non-CBD Blesswell men's skin care products is a significant benefit. We have already achieved substantial success in the U.S. through our retail distribution in Walgreens, Target, and CVS and, as announced yesterday, Amazon. International distribution in Europe and the Middle East, with the potential of future distribution in Latin America and Asia, holds great promise," commented Endexx CEO Todd Davis.

Endexx首席执行官托德·戴维斯评论说:“此次收购对Endexx来说是一个重要的机会,因为能够扩大我们CBD和非CBD百威男士护肤品的分销是一个重大的好处。我们已经通过我们在Walgreens、Target和CVS以及昨天宣布的亚马逊的零售分销在美国取得了巨大的成功。在欧洲和中东的国际分销以及未来在拉丁美洲和亚洲的分销潜力很大。”

Hyla currently markets its proprietary non-nicotine, guarana and L-dopa-based vape products in a wide variety of flavors. The Hyla device is the first non-nicotine vape product to be produced in this manner in the United States and provides an unprecedented 4,500 puffs per device. Introduced in October 2021, Hyla's initial inventory of 140,000 devices was sold out within the first month of availability. The Hyla vape products bear the Underwriters Laboratories global safety certification and is CE approved.

Hyla目前销售其专有的非尼古丁、瓜拉纳和基于左旋多巴的VAPE产品,口味多样。Hyla设备是美国第一个以这种方式生产的非尼古丁电子烟产品,每个设备提供史无前例的4500口烟。Hyla于2021年10月推出,最初库存的14万台设备在上市的第一个月内就销售一空。Hyla Vape产品通过了保险商实验室的全球安全认证,并获得了CE认证。

"Because Hyla's products do not contain any nicotine, and utilize the well-known plant, guarana, and other botanicals, we believe that Hyla's products may create a brand new vape market in the United States that avoids the issues associated with nicotine-based products," continued Mr. Davis. "We look forward to providing product and distribution updates in the near future."

“由于Hyla的产品不含任何尼古丁,并使用了著名的瓜拉纳植物和其他植物,我们相信Hyla的产品可能会在美国创造一个全新的电子烟市场,避免与尼古丁产品相关的问题,”戴维斯继续说。我们期待着在不久的将来提供产品和分销更新。“

For additional information regarding the Hyla control acquisition, please refer to Endexx's Current Report on Form 8-K, which was filed with the United States Securities and Exchange Commission yesterday.

有关收购Hyla控制权的更多信息,请参阅Endexx昨天提交给美国证券交易委员会的8-K表格的最新报告。

About Endexx Corporation

关于Endexx公司

Endexx Corporation develops and distributes all natural, plant-derived topical skincare products. Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness. The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health.

Endexx公司开发和分销所有天然、植物衍生的局部护肤品。它的产品种类繁多,从香膏、面霜、乳液、黄油、面膜、磨砂膏和油,所有这些都以健康皮肤和美容健康为共同目标。这些产品背后的科学包括十年的现场临床研究和实验室工作,以提供含有最佳吸收和支持皮肤健康的成分的功能配方。

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

《1995年私人证券诉讼改革法》下的安全港声明

We caution that any forward-looking statements (as such term is defined in the U.S. Private Securities Litigation Reform Act of 1995) contained in this press release or made by us, our management, or our spokespeople involve risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. Accordingly, our future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Forward-looking statements include, without limitation, statements regarding our future operating results, the implementation and impact of our strategic plans, and our ability to meet environmental, social, and governance goals. Words such as "estimate," "commit," "target," "goal," "project," "plan," "believe," "seek," "strive," "expect," "anticipate," "intend," "potential" and any similar expressions may identify forward-looking statements. Risks associated with the following factors, among others, could affect our financial performance and cause actual results to differ materially from those expressed or implied in any forward-looking statements:

我们提醒,本新闻稿中包含的或由我们、我们的管理层或我们的发言人做出的任何前瞻性声明(根据1995年美国私人证券诉讼改革法中的定义)都涉及风险和不确定因素,并可能因各种因素而发生变化,其中许多因素是我们无法控制的。因此,我们未来的业绩和财务结果可能与任何此类前瞻性陈述中明示或暗示的情况大不相同。前瞻性陈述包括但不限于关于我们未来的经营结果、我们战略计划的实施和影响以及我们实现环境、社会和治理目标的能力的陈述。诸如“估计”、“承诺”、“目标”、“目标”、“项目”、“计划”、“相信”、“寻求”、“努力”、“期望”、“预期”、“打算”、“潜在”等词汇以及任何类似的表述都可能识别前瞻性表述。与以下因素相关的风险可能会影响我们的财务业绩,并导致实际结果与任何前瞻性陈述中明示或暗示的结果大不相同:

Except as may be required by law, we assume no obligation and do not intend to make publicly available any update or other revisions to any of the forward-looking statements contained in this press release to reflect circumstances existing after the date of this press release or to reflect the occurrence of future events, even if experience or future events make it clear that any expected results expressed or implied by those forward-looking statements will not be realized. More information on potential factors that could affect our results is included "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022.

除非法律另有要求,否则我们没有义务也不打算公开提供对本新闻稿中包含的任何前瞻性陈述的任何更新或其他修订,以反映本新闻稿发布之日后存在的情况或未来事件的发生,即使经验或未来事件明确表明,这些前瞻性陈述中明示或暗示的任何预期结果将无法实现。有关可能影响我们业绩的潜在因素的更多信息,请参阅我们于2022年3月31日提交给美国证券交易委员会的Form 10-K年度报告中的“风险因素”。

For further information, please contact:
Endexx Corporation
Endexx@endexx.com
480-595-6900

如需更多信息,请联系:
Endexx公司
邮箱:endexx@endexx.com
480-595-6900

Investors:
Scott Arnold
CORE IR
scotta@coreir.com

投资者:
斯科特·阿诺德
核心红外光谱
邮箱:Scotta@coreir.com

Media:
Jules Abraham
CORE IR
julesa@coreir.com
917-885-7378

媒体:
朱尔斯·亚伯拉罕
核心红外光谱
邮箱:julesa@coreir.com
917-885-7378

Attachment

依附

  • Endexx Corporation
  • Endexx公司

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发